In January 2019, Locus entered a collaboration with Janssen Pharmaceuticals, one of Johnson & Johnson's companies, to develop ...

Viatris (VTRS) stock in focus as the company beats Street forecasts with Q3 2025 financials amid strong emerging market growth and raises its outlook. Read more here.

Viatris on Thursday beat Wall Street estimates for third-quarter results, driven by strong demand for its branded drugs in China and emerging markets, and raised its forecasts for 2025 profit and ...

The TL1a inhibitor duvakitug was effective at 14 weeks in patients who had previous exposure to conventional and advanced ...

Viatris Inc. investors can’t proceed with a lawsuit claiming the drugmaker misrepresented its commitment to its biosimilars business segment, the Third Circuit said Thursday.

Medication company Viatris (NASDAQ:VTRS) beat Wall Street’s revenue expectations in Q3 CY2025, but sales were flat year on year at $3.76 billion. The company’s full-year revenue guidance of $14.1 ...

Pfizer won a $10 billion bidding war for Metsera, beating Danish rival Novo Nordisk, securing access to the U. biotech's experimental obesity drug assets.

In 2019, the global neutropenia treatment market was valued at a staggering $12,602.5 million. This figure encapsulates the substantial demand for innovative therapies aimed at combating ...

President Donald Trump has received updated flu and COVID-19 booster shots in preparation for upcoming travel, the president’s physician announced Oct. 10. Sean P. Barbabella, a U.S. Navy captain, ...

The pharmaceutical sector presents investors with a fundamental choice: embrace the predictable returns of an established ...